CONGRESS ABSTRACT

Background The “fast track” addition (within 48 hours) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to the oral optimized lipid lowering therapy (LLT) during hospitalization for acute coronary syndrome (ACS) has been shown to rapidly achieve the low-density lipoprotein cholesterol (LDL-C) therapeutic targets. However, so far, its efficacy…

Background: Early and intensive low-density lipoprotein cholesterol (LDL-C) reduction after recent acute coronary syndrome (ACS) may reduce recurrent CV event risk. Aim: To evaluate the efficacy in LDL-C lowering added to usual care, of inclisiran administrated in outpatient with recent ACS. Methods: The routine data of 31 patients (27…

Introduction: Despite optimal lipid-lowering therapy, many patients with established cardiovascular disease (CVD) maintain elevated triglyceride (TG) levels, contributing to residual risk. Icosapent ethyl (IPE) has shown clinical benefit in patients with moderate hypertriglyceridemia. This study aimed to evaluate eligibility for IPE treatment based on REDUCE-IT and Italian Drugs Administration…

Background and Objectives: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9-i) are used to reduce LDL cholesterol in dyslipidemic patients who do not adequately respond to traditional therapies. PCSK9 can be inhibited through monoclonal antibodies (Alirocumab, Evolocumab) or siRNA (Inclisiran). Their lipid-lowering efficacy is established, but effects on vascular structure/function…

Background and Objectives: Bempedoic Acid (BA) is one of the most recent therapeutic agents approved for the reduction of LDL-C. Its potential effects on arterial structural and functional parameters have never been evaluated. The aim of this study was to longitudinally evaluate these properties in patients initiating BA therapy…

Background: Bempedoic acid (BA) is approved for the reduction of LDL-C in addition to or instead of statin therapy and ezetimibe. Aim: to assess impact of BA addition to statin therapy at the maximum tolerated dose and ezetimibe 10 mg on the achievement of therapeutic targets of LDL-C values…

Background: Dyslipidemia, a major contributing factor to cardiovascular disease, is increasingly prevalent in patients with renal disease. Low-density lipoprotein cholesterol (LDL-C) have been identified as a primary culprit of cardiovascular risk and individuals with hyperlipidemia face a significantly elevated risk of cardiovascular events. Inclisiran has shown promise in the…